| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Vernakalant |
| Brand | Brinavess® |
| Indication | For haemodynamically stable, symptomatic patients with atrial fibrillation of less than 48 hours duration. |
| Assessment Process | |
| Rapid review commissioned | 26/10/2010 |
| Rapid review completed | 04/11/2010 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 08/04/2011 |
| NCPE assessment completed | 04/05/2011 |
| NCPE assessment outcome | Reimbursement Recommended in Hospital Setting. |
Following review, we recommend reimbursement of vernakalant in the hospital setting.